NEW YORK – Cambridge, Massachusetts-based biopharmaceutical company Vigeo Therapeutics today announced that it has begun clinically testing its first-in-class small peptide drug, VT1021, in its Phase Ib/II clinical trials.
NEW YORK – Cambridge, Massachusetts-based biopharmaceutical company Vigeo Therapeutics today announced that it has begun clinically testing its first-in-class small peptide drug, VT1021, in its Phase Ib/II clinical trials.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.